OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

Clear
Clear
Clear
Clear
Clear
Clear
Clear
Investigator: Fred Grossman

1 Projects | 1 Researchers | $5,000,000 Invested

2024

Coya Therapeutics

Fred Grossman, DO, FAPA

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, 26-Week Study to Evaluate the Safety and Efficacy of COYA 302 for the Treatment of Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Subtype of Frontotemporal Lobar Degeneration (FTLD).

  • Funding Amount: $5,000,000
  • Organization Type: Biotechnology/For Profit
  • Program: Clinical
  • Target: Neuroinflammation
  • Status: Active